[Translation] A multicenter, randomized, controlled, open-label clinical trial of SNG1005 versus investigators' choice of single-agent chemotherapy in the treatment of HER2-negative BCBM patients with brain parenchymal progression after prior whole-brain radiotherapy
比较两组的总生存期(OS); 比较两组的颅内、颅外的无进展生存期(PFS);比较两组颅内、颅外的客观缓解率(ORR);比较两组的颅内缓解持续时间(DoR)和第3和6个月DCR;比较两组颅外DoR;比较两组整体QoL
[Translation] The overall survival (OS) of the two groups was compared; the intracranial and extracranial progression-free survival (PFS) of the two groups were compared; the intracranial and extracranial objective response rates (ORR) of the two groups were compared; the intracranial and extracranial objective response rates (ORR) of the two groups were compared; Duration of internal response (DoR) and DCR at 3 and 6 months; comparison of extracranial DoR between two groups; comparison of overall QoL between two groups